| |
HistoryAmniotic membrane has been used in ophthalmology since the 1940s but because of improper preservation methods available at that time, amniotic membrane’s efficacy had been insufficient and the usage had been very limited. In the late 1990's, Dr. Scheffer C. G. Tseng and his group reintroduced the use of amniotic membrane for ocular surface reconstruction by using a novel method of processing and preservation. AMNIOGRAFT®, in this frozen form, consists of a non-viable matrix, which maintains and preserves the original function, activity, and integrity of the tissue. The effectiveness of this new method has been proven by a growing number of publications and by an increasing popularity within the ophthalmic community in recent years. Click here to see a literature summary. A chronological summary of its uses are listed as follows:
| |
· 1995 Kim and Tseng published a paper experimenting with fresh amniotic membrane for ocular surface reconstruction in rabbit corneas
· Increased usage as reflected by the increasing number of publications supporting the effectiveness of the frozen form introduced by Dr. Tseng in the late 1990's |
Literature SummaryLiterature Summary (click for PDF article) - A detailed literature summary on uses of amniotic membrane in ocular surface reconstruction in recent years provided by Dr. Scheffer CG Tseng.  * You will need Adobe Acrobat Reader® to view the Literature Summary. Please click on the icon to install the reader.
To learn more about the clinical uses of cryopreserved amniotic membrane, visit the Ocular Surface Research and Education Foundation’s website at www.osref.org. |
|